

**LUCY Y. LEI**

Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada

**DEREK S. CHEW, MD**

Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada

**ROBERT S. SHELDON, MD, PhD**

Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada

**SATISH R. RAJ, MD, MSCI, FRCPC**

Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada; Autonomic Dysfunction Center, Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN

# Evaluating and managing postural tachycardia syndrome

## ABSTRACT

Postural tachycardia syndrome (POTS) is a disorder of the autonomic nervous system with many possible causes, characterized by an unexplained increase in heartbeat without change in blood pressure upon standing. Associated cardiac and noncardiac symptoms can severely affect quality of life. Therapy, using a combined approach of diet and lifestyle changes, plus judicious use of medications if needed, can usually improve symptoms and function.

## KEY POINTS

Several POTS subtypes have been recognized, including hypovolemic, neuropathic, and hyperadrenergic forms, overlapping with Ehlers-Danlos syndrome, mast cell activation, and autoimmune syndromes.

Treatment should take a graded approach, beginning with increasing salt and water intake, exercise, and compression stockings.

If needed, consider medications to expand blood volume, slow heart rate, or reduce central sympathetic tone.

Certain medications, including venodilators, diuretics, and serotonin-norepinephrine reuptake inhibitors, can exacerbate symptoms and should be avoided.

Dr. Raj has disclosed consulting for Abbott Laboratories, Boston Scientific Corporation, GE Healthcare, and Lundbeck, and serving on the steering committee for the ADMIRE-ICD trial, funded by GE Healthcare.

doi:10.3949/ccjm.86a.18002

**S**OME PEOPLE, most of them relatively young women, experience lightheadedness, a racing heart, and other symptoms (but not hypotension) when they stand up, in a condition known as postural tachycardia syndrome (POTS).<sup>1</sup> Although not known to shorten life,<sup>1</sup> it can be physically and mentally debilitating.<sup>2,3</sup> Therapy rarely cures it, but a multifaceted approach can substantially improve quality of life.

This review outlines the evaluation and diagnosis of POTS and provides guidance for a therapy regimen.

### ■ HOW IS POTS DEFINED?

POTS is a multifactorial syndrome rather than a specific disease. It is characterized by all of the following<sup>1,4-6</sup>:

- An increase in heart rate of  $\geq 30$  bpm, or  $\geq 40$  bpm for those under age 19, within 10 minutes of standing from a supine position
- Sustained tachycardia ( $> 30$  seconds)
- Absence of orthostatic hypotension (a fall in blood pressure of  $\geq 20/10$  mm Hg)
- Frequent and chronic duration ( $\geq 6$  months).

These features are critical to diagnosis. Hemodynamic criteria in isolation may describe postural tachycardia but are not sufficient to diagnose POTS.

The prevalence of POTS is estimated to be between 0.2% and 1.0%,<sup>7</sup> affecting up to 3 million people in the United States. Most cases arise between ages 13 and 50, with a female-to-male ratio of 5:1.<sup>8</sup>

### ■ MANY NAMES, SAME CONDITION

In 1871, Da Costa<sup>9</sup> described a condition he called “irritable heart syndrome” that had characteristics similar to those of POTS, including

extreme fatigue and exercise intolerance. Decades later, Lewis<sup>10</sup> and Wood<sup>11</sup> provided more detailed descriptions of the disorder, renaming it “soldier’s heart” or “Da Costa syndrome.” As other cases were documented, more terms arose, including “effort syndrome” and “mitral valve prolapse syndrome.”

In 1982, Rosen and Cryer<sup>12</sup> were the first to use the term “postural tachycardia syndrome” for patients with disabling tachycardia upon standing without orthostatic hypotension. In 1986, Fouad et al<sup>13</sup> described patients with postural tachycardia, orthostatic intolerance, and a small degree of hypotension as having “idiopathic hypovolemia.”

In 1993, Schondorf and Low<sup>14</sup> established the current definition of POTS, leading to increased awareness and research efforts to understand its pathophysiology.

### ■ MULTIFACTORIAL PATHOPHYSIOLOGY

During the last 2 decades, several often-overlapping forms of POTS have been recognized, all of which share a final common pathway of sustained orthostatic tachycardia.<sup>15–19</sup> In addition, a number of common comorbidities were identified through review of large clinic populations of POTS.<sup>20,21</sup>

#### Hypovolemic POTS

Up to 70% of patients with POTS have hypovolemia. The average plasma volume deficit is about 13%, which typically causes only insignificant changes in heart rate and norepinephrine levels while a patient is supine. However, blood pooling associated with upright posture further compromises cardiac output and consequently increases sympathetic nerve activity. Abnormalities in the renin-angiotensin-aldosterone volume regulation system are also suspected to impair sodium retention, contributing to hypovolemia.<sup>1,22</sup>

#### Neuropathic POTS

About half of patients with POTS have partial sympathetic denervation (particularly in the lower limbs) and inadequate vasoconstriction upon standing, leading to reduced venous return and stroke volume.<sup>17,23</sup> A compensatory increase in sympathetic tone results in tachycardia to maintain cardiac output and blood pressure.

#### Hyperadrenergic POTS

Up to 50% of patients with POTS have high norepinephrine levels ( $\geq 600$  pg/mL) when upright. This subtype, hyperadrenergic POTS, is characterized by an increase in systolic blood pressure of at least 10 mm Hg within 10 minutes of standing, with concomitant tachycardia that can be similar to or greater than that seen in nonhyperadrenergic POTS. Patients with hyperadrenergic POTS tend to report more prominent symptoms of sympathetic activation, such as palpitations, anxiety, and tremulousness.<sup>24,25</sup>

#### Norepinephrine transporter deficiency

The norepinephrine transporter (NET) is on the presynaptic cleft of sympathetic neurons and serves to clear synaptic norepinephrine. NET deficiency leads to a hyperadrenergic state and elevated sympathetic nerve activation.<sup>18</sup> NET deficiency may be induced by common antidepressants (eg, tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors) and attention-deficit disorder medications.<sup>4</sup>

#### Mast cell activation syndrome

The relationship between mast cell activation syndrome and POTS is poorly understood.<sup>4,26</sup> Mast cell activation syndrome has been described in a subset of patients with POTS who have sinus tachycardia accompanied by severe episodic flushing. Patients with this subtype have a hyperadrenergic response to postural change and elevated urine methylhistamine during flushing episodes.

Patients with mast cell activation syndrome tend to have strong allergic symptoms and may also have severe gastrointestinal problems, food sensitivities, dermatographism, and neuropathy. Diagnosis can be difficult, as the condition is associated with numerous markers with varying sensitivity and specificity.

#### Autoimmune origin

A significant minority of patients report a viral-like illness before the onset of POTS symptoms, suggesting a possible autoimmune-mediated or inflammatory cause. Also, some autoimmune disorders (eg, Sjögren syndrome) can present with a POTS-like manifestation.

Research into the role of autoantibodies in the pathophysiology of POTS offers the poten-

**POTS is a multifactorial syndrome rather than a specific disease**

tial to develop novel therapeutic targets. Auto-antibodies that have been reported in POTS include those against M1 to M3 muscarinic receptors (present in over 87% of patients with POTS),<sup>27</sup> cardiac lipid raft-associated proteins,<sup>28</sup> adrenergic G-protein coupled receptors, alpha-1-adrenergic receptors, and beta-1- and beta-2-adrenergic receptors.<sup>29</sup> Although commercial enzyme-linked immunosorbent assays can assess for these antibody fragments, it is not known whether targeting the antibodies improves outcomes. At this time, antibody testing for POTS should be confined to the research setting.

### ■ LINKS TO OTHER SYNDROMES

POTS is often associated with other conditions whose symptoms cannot be explained by postural intolerance or tachycardia.

**Ehlers-Danlos syndromes** are a group of inherited heterogeneous disorders involving joint hypermobility, skin hyperextensibility, and tissue fragility.<sup>30</sup> The hypermobile subtype is most commonly associated with POTS, with patients often having symptoms of autonomic dysregulation and autonomic test abnormalities.<sup>31–33</sup> Patients with POTS may have a history of joint subluxations, joint pain, cervical instability, and spontaneous epidural leaks. The reason for the overlap between the two syndromes is not clear.

**Chronic fatigue syndrome** is characterized by persistent fatigue that does not resolve with rest and is not necessarily associated with orthostatic changes. More than 75% of patients with POTS report general fatigue as a major complaint, and up to 23% meet the full criteria for chronic fatigue syndrome.<sup>34</sup>

### ■ DIAGNOSTIC STRATEGY

A patient presenting with symptoms suggestive of POTS should first undergo a detailed history and physical examination. Other causes of sinus tachycardia should be considered.

#### Detailed history, symptom review

The history should focus on determining symptom burden, including tachycardia onset, frequency, severity, and triggers; the presence of syncope; and the impact of symptoms on daily function and quality of life.

**TABLE 1**

### Typical symptoms of postural tachycardia syndrome

#### Cardiac symptoms

Palpitations  
Lightheadedness  
Chest discomfort  
Dyspnea

#### Noncardiac symptoms

Mental clouding (“brain fog”)  
Headache  
Nausea  
Tremulousness  
Blurred or tunnel vision  
Sleep disturbances  
Fatigue  
Presyncope  
Gastrointestinal pain, heartburn, diarrhea, constipation

POTS-associated orthostatic intolerance manifests with cardiac and noncardiac symptoms (Table 1).

Presyncope and its associated symptoms occur in less than one-third of patients with POTS, and syncope is not a principal feature.<sup>4</sup> If syncope is the predominant complaint, alternative causes should be investigated. The usual cause of syncope in the general population is thought to be vasovagal.

In addition to orthostatic intolerance, gastrointestinal disturbances are common in POTS, presenting as abdominal pain, heartburn, irregular bowel movements, diarrhea, or constipation. Symptoms of gastroparesis are less common. Gastrointestinal symptoms tend to be prolonged, lasting hours and occurring multiple times a week. They tend not to improve in the supine position.<sup>35</sup>

POTS-associated symptoms may develop insidiously, but patients often report onset after an acute stressor such as pregnancy, major surgery, or a presumed viral illness.<sup>4</sup> Whether these putative triggers are causative or coincidental is unknown. Symptoms of orthostatic

**Hypovolemia occurs in up to 70% of patients**

TABLE 2

**Differential diagnosis of postural tachycardia syndrome symptoms**

- Hyperthyroidism
- Infection
- Pheochromocytoma
- Inappropriate sinus tachycardia
- Acute dehydration
- Exercise
- Physical deconditioning
- Panic attacks
- Pain
- Alcohol
- Caffeine
- Medication-induced or exacerbated

Information from references 39–41.

**POTS is often associated with Ehlers-Danlos syndrome**

intolerance tend to be exacerbated by dehydration, heat, alcohol, exercise, and menstruation.<sup>36,37</sup>

Consider the family history: 1 in 8 patients with POTS reports familial orthostatic intolerance,<sup>38</sup> suggesting a genetic role in some patients. Inquire about symptoms or a previous diagnosis of Ehlers-Danlos syndrome and mast cell activation syndrome.

**Consider other conditions**

Other causes of orthostatic tachycardia are listed in **Table 2**.<sup>39–41</sup> Most can be diagnosed with a careful history, physical examination, and laboratory tests. Two of the more challenging diagnoses are described below.

**Pheochromocytoma** causes hyperadrenergic symptoms (eg, palpitations, lightheadedness) like those in POTS, but patients with pheochromocytoma typically have these symptoms while supine. Pheochromocytoma is also characterized by plasma norepinephrine levels much higher than in POTS.<sup>4</sup> Plasma metanephrine testing helps diagnose or rule out pheochromocytoma.<sup>5</sup>

**Inappropriate sinus tachycardia**, like pheochromocytoma, also has clinical features similar to those of POTS, as well as tachycardia

present when supine. It involves higher sympathetic tone and lower parasympathetic tone compared with POTS; patients commonly have a daytime resting heart rate of at least 100 bpm or a 24-hour mean heart rate of at least 90 bpm.<sup>1,42</sup> While the intrinsic heart rate is heightened in inappropriate sinus tachycardia, it is not different between POTS patients and healthy individuals.<sup>42,43</sup> Distinguishing POTS from inappropriate sinus tachycardia is further complicated by the broad inclusion criteria of most studies of inappropriate sinus tachycardia, which failed to exclude patients with POTS.<sup>44</sup> The Heart Rhythm Society recently adopted distinct definitions for the 2 conditions.<sup>1</sup>

**Physical examination: Focus on vital signs**

The most critical component of the physical examination is thorough measurement of orthostatic vital signs (**Figure 1**). Blood pressure and heart rate should be measured while the patient has been supine for at least 5 minutes, and again after being upright for 1, 3, 5, and 10 minutes. These measurements determine if orthostatic hypotension is present and whether the patient meets the heart rate criteria for POTS. Patients with POTS tend to experience greater orthostatic tachycardia in the morning, so evaluation early in the day optimizes diagnostic sensitivity.<sup>5</sup>

Dependent acrocyanosis—dark red-blue discoloration of the lower legs that is cold to the touch—occurs in about half of patients with POTS upon standing.<sup>4</sup> Dependent acrocyanosis is associated with joint hypermobility and Ehlers-Danlos syndrome, so these conditions should also be considered if findings are positive.

**Laboratory testing for other causes**

Laboratory testing is used mainly to detect primary causes of sinus tachycardia. Tests should include:

- Complete blood cell count with hematocrit (for severe anemia)
- Thyroid-stimulating hormone level (for hyperthyroidism)
- Electrolyte panel (for significant electrolyte disturbances).

Evidence is insufficient to support routinely measuring the vitamin B<sub>12</sub> level, iron indices, and serum markers for celiac disease, although these may be done if the history or

physical examination suggests related problems.<sup>4</sup> Sicca symptoms (severe dry eye or dry mouth) should trigger evaluation for Sjögren syndrome.

### Electrocardiography needed

Electrocardiography should be performed to investigate for cardiac conduction abnormalities as well as for resting markers of a supraventricular tachyarrhythmia. Extended ambulatory (Holter) monitoring may be useful to evaluate for a transient reentrant tachyarrhythmia<sup>4</sup>; however, it does not record body position, so it can be difficult to determine if detected episodes of tachycardia are related to posture.

### Additional testing for select cases


Further investigation is usually not needed to diagnose POTS but should be considered in some cases. Advanced tests are typically performed at a tertiary care referral center and include:

- Quantitative sensory testing to evaluate for small-fiber neuropathy (ie, Quantitative Sudomotor Axon Reflex Test, or QSART), which occurs in the neuropathic POTS subtype
- Formal autonomic function testing to characterize neurovascular responsiveness
- Supine and standing plasma norepinephrine levels (fractionated catecholamines) to characterize the net activation of the sympathetic nervous system
- Blood volume assessments to assess hypovolemia
- Formal exercise testing to objectively quantify exercise capacity.

### GRADED MANAGEMENT

No single universal gold-standard therapy exists for POTS, and management should be individually determined with the primary goals of treating symptoms and restoring function. A graded approach should be used, starting with conservative nonpharmacologic therapies and adding medications as needed.

While the disease course varies substantially from patient to patient, proper management is strongly associated with eventual symptom improvement.<sup>1</sup>



**Figure 1.** Results of head-up tilt-table (HUT) testing in a healthy person (top) and in a patient with postural tachycardia syndrome (POTS) (bottom). Upon passive head-up tilting, the heart rate increases in POTS by at least 30 bpm but remains largely stable in healthy individuals. Orthostatic hypotension (a fall in blood pressure of  $\geq 20/10$  mm Hg) does not occur in either patient.

### NONPHARMACOLOGIC STEPS FIRST

A multipronged nonpharmacologic approach should be used for all patients before resorting to medications (Table 3). In an observational study, most patients reported that such interventions were more helpful than medications.<sup>45</sup> The following elements are recommended:

#### Education

Patients should be informed of the nature of their condition and referred to appropriate healthcare personnel. POTS is a chronic illness requiring individualized coping strategies,

**TABLE 3**

**Nonpharmacologic treatments for postural tachycardia syndrome**

Therapy	Dosage	Pathologic mechanisms addressed	Potential drawbacks	Comments
<b>Exercise</b>	≥ 30 min at least 3 times a week	All	Worsened symptoms at the outset, prolonged fatigue	Gradually progress from non-upright to upright endurance and resistance exercises
<b>Dietary fluid</b>	2–3 L per day	All	Hyponatremia	
<b>Dietary salt</b>	10–12 g per day	All	Difficult to augment sufficiently through diet alone	Supplement with sodium chloride tablets, if necessary
<b>Salt tablets</b>	1 g tablet 3 times daily	Hypovolemia	Poor taste, nausea, dyspepsia	Recommended for use after meals
<b>Acute intravenous normal saline</b>	1 L over 1–3 hours	Hypovolemia	Inconvenient, medical setting required	Heart Rhythm Society Consensus Statement class IIa recommendation (benefit probably exceeds risk)
<b>Chronic intravenous normal saline</b>	1 L every 2 days	Hypovolemia	Access complications and infection with central line	Heart Rhythm Society Consensus Statement class III recommendation (recommends against)

**First try non-pharmacologic approaches**

intensive physician interaction, and support of a multidisciplinary team. Patients and family members can be reassured that most symptoms improve over time with appropriate diagnosis and treatment.<sup>1</sup> Patients should be advised to avoid aggravating triggers and activities.

**Exercise**

Exercise programs are encouraged but should be introduced gradually, as physical activity can exacerbate symptoms, especially at the outset. Several studies have reported benefits from a short-term (3-month) program, in which the patient gradually progresses from non-upright exercise (eg, rowing machine, recumbent cycle, swimming) to upright endurance exercises. At the end of these programs, significant cardiac remodeling, improved quality of life, and reduced heart rate responses to standing have been reported, and benefits have been reported to persist in patients who continued exercising after the 3-month study period.<sup>46,47</sup>

Despite the benefits of exercise interventions, compliance is low.<sup>46,47</sup> To prevent early discouragement, patients should be advised that it can take 4 to 6 weeks of continued exercise before benefits appear. Patients are

encouraged to exercise every other day for 30 minutes or more. Regimens should primarily focus on aerobic conditioning, but resistance training, concentrating on thigh muscles, can also help. Exercise is a treatment and not a cure, and benefits can rapidly disappear if regular activity (at least 3 times per week) is stopped.<sup>48</sup>

**Compression stockings**

Compression stockings help reduce peripheral venous pooling and enhance venous return to the heart. Waist-high stockings with compression of at least 30 to 40 mm Hg offer the best results.

**Diet**

Increased fluid and salt intake is advisable for patients with suspected hypovolemia. At least 2 to 3 L of water accompanied by 10 to 12 g of daily sodium intake is recommended.<sup>1</sup> This can usually be accomplished with diet and salt added to food, but salt tablets can be used if the patient prefers. The resultant plasma volume expansion may help reduce the reflex tachycardia upon standing.<sup>49</sup>

### Check medications

The clinician should review—and perhaps discontinue—medications the patient is already taking that may exacerbate tachycardia or related symptoms (Table 4).<sup>50</sup> Venodilators decrease preload, thereby reducing cardiac output and blood pressure, which triggers compensatory tachycardia. Diuretics can reduce effective blood volume and lower preload, leading to worsened symptoms mediated by hypovolemia.

### Rescue therapy with saline infusion

Intravenous saline infusion can augment blood volume in patients who are clinically decompensated and present with severe symptoms.<sup>1</sup> Intermittent infusion of 1 L of normal saline has been found to significantly reduce orthostatic tachycardia and related symptoms in patients with POTS, contributing to improved quality of life.<sup>51,52</sup>

Chronic saline infusions are not recommended for long-term care because of the risk of access complications and infection.<sup>1</sup> Moak et al<sup>53</sup> reported a high rate of bacteremia in a cohort of children with POTS with regular saline infusions, most of whom had a central line. On the other hand, Ruzieh et al<sup>54</sup> reported significantly improved symptoms with regular saline infusions without a high rate of complications, but patients in this study received infusions for only a few months and through a peripheral intravenous catheter.

## ■ DRUG THERAPY

Drug therapy for POTS should be used only if nonpharmacologic interventions do not adequately relieve symptoms. Given the heterogeneity of POTS, treatment should be tailored to the patient's underlying pathophysiology, key clinical features, and comorbidities. These considerations should guide the initial selection of medications, with adjustments as needed to alleviate adverse effects (Table 5).

No medications are approved by the US Food and Drug Administration (FDA) or Health Canada specifically for treating POTS, making all pharmacologic recommendations off-label. Although the drugs discussed below have been evaluated for POTS in controlled laboratory settings, they have yet to be tested in robust clinical trials.

TABLE 4

### Medications that can exacerbate postural tachycardia syndrome

Antidepressants (serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, and tricyclic antidepressants at higher doses)

Antipsychotic agents (phenothiazines)

Anxiolytic agents

Attention deficit medications

Diuretics

Venodilators and vasodilators

Stimulants (including caffeine, nicotine)

### Blood volume expansion

Several drugs expand blood volume, which may reduce orthostatic tachycardia.

**Fludrocortisone** is a synthetic aldosterone analogue that enhances sodium and water retention. Although one observational study found that it normalizes hemodynamic changes in response to orthostatic stress, no high-level evidence exists for its effectiveness for POTS.<sup>55</sup> It is generally well tolerated, although possible adverse effects include hyperkalemia, hypertension, fatigue, nausea, headache, and edema.<sup>5,56</sup>

**Desmopressin** is a synthetic version of a natural antidiuretic hormone that increases kidney-mediated free-water reabsorption without sodium retention. It significantly reduces upright heart rate in patients with POTS and improves symptom burden. Although potential adverse effects include edema and headache, hyponatremia is the primary concern with daily use, especially with the increased water intake advised for POTS.<sup>57</sup> Patients should be advised to use desmopressin no more than once a week for the acute improvement of symptoms. Intermittent monitoring of serum sodium levels is recommended for safety.

**Erythropoietin** replacement has been suggested for treating POTS to address the significant deficit in red blood cell volume. Although erythropoietin therapy has a direct vasoconstrictive effect and largely improves red blood cell volume in patients with POTS, it does not expand plasma volume, so ortho-

**Long-term use of saline infusion is not recommended**

**TABLE 5**

**Pharmacologic treatments for postural tachycardia syndrome**

Therapy	Dosage	Pathologic mechanism addressed	Potential drawbacks	Comments
<b>Blood volume expanders</b>				
<b>Fludrocortisone</b>	0.05–0.1 mg twice daily	Hypovolemia	Hypokalemia, hypertension, fatigue, headache, fluid retention, edema	
<b>Desmopressin</b>	0.1–0.2 mg 3 times daily	Hypovolemia	Hyponatremia, headache, edema	Only for occasional use; must monitor blood sodium
<b>Erythropoietin</b>	2,000–3,000 IU subcutaneously 1–3 times per week	Hypovolemia	High cost, requires injection, risk of vascular complications	Reserved for patients with symptoms refractory to more common treatments
<b>Heart rate-lowering agents</b>				
<b>Propranolol</b>	10–20 mg 3–4 times daily	All	Hypotension, fatigue, drowsiness, wheezing	Not well tolerated at higher dosages
<b>Ivabradine</b>	5–7.5 mg twice daily	All	Palpitations, headache, dizziness, constipation	
<b>Central nervous system sympatholytics</b>				
<b>Clonidine</b>	0.05–0.2 mg twice daily	Hyperadrenergic	Mental clouding, fatigue, drowsiness, constipation	Can be associated with rebound hypertension and tachycardia
<b>Methyldopa</b>	125 mg once or twice daily	Hyperadrenergic	Hypotension, fatigue, headache, drowsiness, constipation	Rare lupus-like syndrome reported
<b>Other drugs</b>				
<b>Midodrine</b>	5–15 mg every 4 hours, 3 times daily only	Neuropathic	Hypertension, goose bumps, urinary retention	Not recommended for use within 4-5 hours of sleep
<b>Pyridostigmine</b>	30–60 mg 3 times daily	All	Abdominal cramping, diarrhea, increased sweating	May increase gastrointestinal motility
<b>Droxidopa</b>	100–600 mg 3 times daily	All	Nausea, palpitations, urinary symptoms	May worsen tachycardia
<b>Modafinil</b>	100–200 mg twice daily	“Brain fog”	Headache, dizziness, anxiety, insomnia	May improve cognitive symptoms

static tachycardia is not itself reduced.<sup>22</sup> Nevertheless, it may significantly improve POTS symptoms refractory to more common methods of treatment, and it should be reserved for such cases. In addition to the lack of effect on

orthostatic tachycardia, drawbacks to using erythropoietin include its high cost, the need for subcutaneous administration, and the risk of life-threatening complications such as myocardial infarction and stroke.<sup>58,59</sup>

### Heart rate-lowering agents

**Propranolol**, a nonselective beta-adrenergic antagonist, can significantly reduce standing heart rate and improve symptoms at low dosages (10–20 mg). Higher dosages can further restrain orthostatic tachycardia but are not as well tolerated, mainly due to hypotension and worsening of existing symptoms such as fatigue.<sup>60</sup> Regular-acting propranolol works for about 4 to 5 hours per dose, so full-day coverage often requires dosing 4 times per day.

**Ivabradine** is a selective blocker of the “funny” ( $I_f$ ) channel that reduces the sinus node firing rate without affecting blood pressure, so it slows heart rate without causing supine hypertension or orthostatic hypotension.

A retrospective case series found that 60% of patients with POTS treated with ivabradine reported symptomatic improvement, and all patients experienced reduced tachycardia with continued use.<sup>61</sup> Ivabradine has not been compared with placebo or propranolol in a randomized controlled trial, and it has not been well studied in pregnancy and so should be avoided because of potential teratogenic effects.

When prescribing ivabradine for women of childbearing age, a negative pregnancy test may be documented prior to initiation of therapy, and the use of highly effective methods of contraception is recommended. Ivabradine should be avoided in women contemplating pregnancy. Insurance coverage can limit access to ivabradine in the United States.

### Central nervous system sympatholytics

Patients with prominent hyperadrenergic features may benefit from central sympatholytic agents. However, these drugs may not be well tolerated in patients with neuropathic POTS because of the effects of reduced systemic vascular resistance<sup>5</sup> and the possible exacerbation of drowsiness, fatigue, and mental clouding.<sup>4</sup> Patients can be extremely sensitive to these medications, so they should initially be prescribed at the lowest dose, then gradually increased as tolerated.

**Clonidine**, an alpha-2-adrenergic agonist, decreases central sympathetic tone. In hyperadrenergic patients, clonidine can stabilize

heart rate and blood pressure, thereby reducing orthostatic symptoms.<sup>62</sup>

**Methyldopa** has effects similar to those of clonidine but is easier to titrate owing to its longer half-life.<sup>63</sup> Methyldopa is typically started at 125 mg at bedtime and increased to 125 mg twice daily, if tolerated.

### Other agents

**Midodrine** is a prodrug. The active form, an alpha-1-adrenergic agonist, constricts peripheral veins and arteries to increase vascular resistance and venous return, thereby reducing orthostatic tachycardia.<sup>52</sup> It is most useful in patients with impaired peripheral vasoconstriction (eg, neuropathic POTS) and may be less effective in those with hyperadrenergic POTS.<sup>64</sup> Major limitations of midodrine include worsening supine hypertension and possible urinary retention.<sup>39</sup>

Because of midodrine’s short half-life, frequent dosing is required during daytime hours (eg, 8 AM, noon, and 4 PM), but it should not be taken within 4 to 5 hours of sleep because of the risk of supine hypertension. Midodrine is typically started at 2.5 to 5 mg per dose and can be titrated up to 15 mg per dose.

Midodrine is an FDA pregnancy category C drug (adverse effects in pregnancy seen in animal models, but evidence lacking in humans). While ideally it should be avoided, we have used it safely in pregnant women with disabling POTS symptoms.

**Pyridostigmine**, an acetylcholinesterase inhibitor, increases cardiovagal tone and possibly sympathetic tone. It has been reported to significantly reduce standing heart rate and improve symptom burden in patients with POTS.<sup>65</sup> However, pyridostigmine increases gastrointestinal mobility, leading to severe adverse effects in over 20% of patients, including abdominal cramps, nausea, and diarrhea.<sup>66</sup>

**Droxidopa**, a synthetic amino acid precursor of norepinephrine, improves dizziness and fatigue in POTS with minimal effects on blood pressure.<sup>67</sup>

**Modafinil**, a psychostimulant, may improve POTS-associated cognitive symptoms.<sup>4</sup> It also raises upright blood pressure without significantly worsening standing heart rate or acute orthostatic symptoms.<sup>68</sup>

**POTS rarely resolves without ongoing treatment**

■ **EFFECTS OF COMORBID DISORDERS ON MANAGEMENT**

**Ehlers-Danlos syndrome**

Pharmacologic approaches to POTS should not be altered based on the presence of Ehlers-Danlos syndrome, but because many of these patients are prone to joint dislocation, exercise prescriptions may need adjusting.

A medical genetics consult is recommended for patients with Ehlers-Danlos syndrome. Although the hypermobile type (the form most commonly associated with POTS) is not associated with aortopathy, it can be confused with classical and vascular Ehlers-Danlos syndromes, which require serial aortic screening.<sup>30</sup>

**Mast cell activation syndrome**

Consultation with an allergist or immunologist may help patients with severe symptoms.

**Autoantibodies and autoimmunity**

Treatment of the underlying disorder is recommended and can result in significantly improved POTS symptoms.

■ **SPECIALTY CARE REFERRAL**

POTS can be challenging to manage. Given

the range of physiologic, emotional, and functional distress patients experience, it often requires significant physician time and multidisciplinary care. Patients with continued severe or debilitating symptoms may benefit from referral to a tertiary-care center with experience in autonomic nervous system disorders.

■ **PROGNOSIS**

Limited data are available on the long-term prognosis of POTS, and more studies are needed in pediatric and adult populations. No deaths have been reported in the handful of published cases of POTS in patients older than 50.<sup>1</sup> Some pediatric studies suggest that some teenagers “outgrow” their POTS. However, these data are not robust, and an alternative explanation is that as they get older, they see adult physicians for their POTS symptoms and so are lost to study follow-up.<sup>6,44,69</sup>

We have not often seen POTS simply resolve without ongoing treatment. However, in our experience, most patients have improved symptoms and function with multimodal treatment (ie, exercise, salt, water, stockings, and some medications) and time. ■

■ **REFERENCES**

1. Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. *Heart Rhythm* 2015; 12(6):e41–e63. doi:10.1016/j.hrthm.2015.03.029
2. Bagai K, Song Y, Ling JF, et al. Sleep disturbances and diminished quality of life in postural tachycardia syndrome. *J Clin Sleep Med* 2011; 7(2):204–210. PMID:21509337
3. Benrud-Larson LM, Dewar MS, Sandroni P, Rummans TA, Haythornthwaite JA, Low PA. Quality of life in patients with postural tachycardia syndrome. *Mayo Clin Proc* 2002; 77(6):531–537. doi:10.4065/77.6.531
4. Raj SR. Postural tachycardia syndrome (POTS). *Circulation* 2013; 127(23):2336–2342. doi:10.1161/CIRCULATIONAHA.112.144501
5. Raj SR. The postural tachycardia syndrome (POTS): pathophysiology, diagnosis & management. *Indian Pacing Electrophysiol J* 2006; 6(2):84–99. PMID:16943900
6. Singer W, Sletten DM, Opfer-Gehrking TL, Brands CK, Fischer PR, Low PA. Postural tachycardia in children and adolescents: what is abnormal? *J Pediatr* 2012; 160(2):222–226. doi:10.1016/j.jpeds.2011.08.054
7. Mar PL, Raj SR. Neuronal and hormonal perturbations in postural tachycardia syndrome. *Front Physiol* 2014; 5:220. doi:10.3389/fphys.2014.00220
8. Garland EM, Raj SR, Black BK, Harris PA, Robertson D. The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome. *Neurology* 2007; 69(8):790–798. doi:10.1212/01.wnl.0000267663.05398.40
9. Da Costa JM. On irritable heart: a clinical study of a form of functional cardiac disorder and its consequences. *Am J Med Sci* 1871; 61(121):2–52.
10. Lewis T. The tolerance of physical exertion, as shown by soldiers suffering from so-called “irritable heart.” *Br Med J* 1918; 1(2987):363–365. PMID:20768980
11. Wood P. Da Costa’s syndrome (or effort syndrome): lecture I. *Br Med J* 1941; 1(4194):767–772. PMID:20783672
12. Rosen SG, Cryer PE. Postural tachycardia syndrome. Reversal of sympathetic hyperresponsiveness and clinical improvement during sodium loading. *Am J Med* 1982; 72(5):847–850.
13. Fouad FM, Tadana-Thome L, Bravo EL, Tarazi RC. Idiopathic hypovolemia. *Ann Intern Med* 1986; 104(3):298–303. PMID:3511818
14. Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? *Neurology* 1993; 43(1):132–137. PMID:8423877
15. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. *N Engl J Med* 2000; 343(12):847–855. doi:10.1056/NEJM200009213431204
16. Raj SR, Robertson D. Blood volume perturbations in the postural tachycardia syndrome. *Am J Med Sci* 2007; 334(1):57–60. doi:10.1097/MAJ.0b013e318063c6c0
17. Jacob G, Costa F, Shannon JR, et al. The neuropathic postural tachycardia syndrome. *N Engl J Med* 2000; 343(14):1008–1014. doi:10.1056/NEJM200010053431404
18. Shannon JR, Flattem NL, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. *N Engl J Med* 2000; 342(8):541–549. doi:10.1056/NEJM200002243420803
19. Jones PK, Shaw BH, Raj SR. Clinical challenges in the diagnosis and management of postural tachycardia syndrome. *Pract Neurol* 2016;

- 16(6):431–438. doi:10.1136/practneurol-2016-001405
20. **Gunning WT, Karabin BL, Blomquist TM, Grubb BP.** Postural orthostatic tachycardia syndrome is associated with platelet storage pool deficiency. *Medicine (Baltimore)* 2016; 95(37):e4849. doi:10.1097/MD.00000000000004849
  21. **Kanjwal K, Sheikh M, Karabin B, Kanjwal Y, Grubb BP.** Neurocardiogenic syncope coexisting with postural orthostatic tachycardia syndrome in patients suffering from orthostatic intolerance: a combined form of autonomic dysfunction. *Pacing Clin Electrophysiol* 2011; 34(5):549–554. doi:10.1111/j.1540-8159.2010.02994.x
  22. **Raj SR, Biaggioni I, Yamhure PC, et al.** Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. *Circulation* 2005; 111(13):1574–1582. doi:10.1161/01.CIR.0000160356.97313.5D
  23. **Gibbons CH, Bonyhay I, Benson A, Wang N, Freeman R.** Structural and functional small fiber abnormalities in the neuropathic postural tachycardia syndrome. *PLoS One* 2013; 8(12):e84716. doi:10.1371/journal.pone.0084716
  24. **Low PA, Sandroni P, Joyner M, Shen WK.** Postural tachycardia syndrome (POTS). *J Cardiovasc Electrophysiol* 2009; 20(3):352–358. doi:10.1111/j.1540-8167.2008.01407.x
  25. **Kanjwal K, Saeed B, Karabin B, Kanjwal Y, Grubb BP.** Clinical presentation and management of patients with hyperadrenergic postural orthostatic tachycardia syndrome. A single center experience. *Cardiol J* 2011; 18(5):527–531. PMID:21947988
  26. **Shibao C, Arzubiaga C, Roberts J, et al.** Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. *Hypertension* 2005; 45(3):385–390. doi:10.1161/01.HYP.0000158259.68614.40
  27. **Dubey D, Hopkins S, Vernino S.** M1 and M2 muscarinic receptor antibodies among patients with postural orthostatic tachycardia syndrome: potential disease biomarker [abstract]. *J Clin Neuromuscul Dis* 2016; 17(3):179S.
  28. **Wang XL, Ling TY, Charlesworth MC, et al.** Autoimmunoreactive IgGs against cardiac lipid raft-associated proteins in patients with postural orthostatic tachycardia syndrome. *Transl Res* 2013; 162(1):34–44. doi:10.1016/j.trsl.2013.03.002
  29. **Li H, Yu X, Liles C, et al.** Autoimmune basis for postural tachycardia syndrome. *J Am Heart Assoc* 2014; 3(1):e000755. doi:10.1161/JAHA.113.000755
  30. **Malfait F, Francomano C, Byers P, et al.** The 2017 international classification of the Ehlers-Danlos syndromes. *Am J Med Genet C Semin Med Genet* 2017; 175(1):8–26. doi:10.1002/ajmg.c.31552
  31. **Wallman D, Weinberg J, Hohler AD.** Ehlers-Danlos syndrome and postural tachycardia syndrome: a relationship study. *J Neurol Sci* 2014; 340(1-2):99–102. doi:10.1016/j.jns.2014.03.002
  32. **De Wandele I, Calders P, Peersman W, et al.** Autonomic symptom burden in the hypermobility type of Ehlers-Danlos syndrome: a comparative study with two other EDs types, fibromyalgia, and healthy controls. *Semin Arthritis Rheum* 2014; 44(3):353–361. doi:10.1016/j.semarthrit.2014.05.013
  33. **Gazit Y, Nahir AM, Grahame R, Jacob G.** Dysautonomia in the joint hypermobility syndrome. *Am J Med* 2003; 115(1):33–40. PMID:12867232
  34. **Okamoto LE, Raj SR, Peltier A, et al.** Neurohumoral and haemodynamic profile in postural tachycardia and chronic fatigue syndromes. *Clin Sci (Lond)* 2012; 122(4):183–192. doi:10.1042/CS20110200
  35. **Wang LB, Culbertson CJ, Deb A, Morgenshtern K, Huang H, Hohler AD.** Gastrointestinal dysfunction in postural tachycardia syndrome. *J Neurol Sci* 2015; 359(1-2):193–196. doi:10.1016/j.jns.2015.10.052
  36. **Raj S, Sheldon R.** Management of postural tachycardia syndrome, inappropriate sinus tachycardia and vasovagal syncope. *Arrhythm Electrophysiol Rev* 2016; 5(2):122–129. doi:10.15420/AER.2016.7.2
  37. **Peggs KJ, Nguyen H, Enayat D, Keller NR, Al-Hendy A, Raj SR.** Gynecologic disorders and menstrual cycle lightheadedness in postural tachycardia syndrome. *Int J Gynaecol Obstet* 2012; 118(3):242–246. doi:10.1016/j.ijgo.2012.04.014
  38. **Thieben MJ, Sandroni P, Sletten DM, et al.** Postural orthostatic tachycardia syndrome: the Mayo Clinic experience. *Mayo Clin Proc* 2007; 82(3):308–313. doi:10.4065/82.3.308
  39. **Deb A, Morgenshtern K, Culbertson CJ, Wang LB, Hohler AD.** A survey-based analysis of symptoms in patients with postural orthostatic tachycardia syndrome. *J Am Coll Cardiol* 2015; 28(7):157–159. PMID:25829642
  40. **Ertek S, Cicero AF.** Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology. *Arch Med Sci* 2013; 9(5):944–952. doi:10.5114/aoms.2013.38685
  41. **Rangno RE, Langlois S.** Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. *Br J Clin Pharmacol* 1982; 13(suppl 2):345S–351S. PMID:6125187
  42. **Nwazue VC, Paranjape SY, Black BK, et al.** Postural tachycardia syndrome and inappropriate sinus tachycardia: role of autonomic modulation and sinus node automaticity. *J Am Heart Assoc* 2014; 3(2):e000700. doi:10.1161/JAHA.113.000700
  43. **Morillo CA, Klein GJ, Thakur RK, Li H, Zardini M, Yee R.** Mechanism of “inappropriate” sinus tachycardia. Role of sympathovagal balance. *Circulation* 1994; 90(2):873–877. PMID:7913886
  44. **Grubb BP.** Postural tachycardia syndrome. *Circulation* 2008; 117(21):2814–2817. doi:10.1161/CIRCULATIONAHA.107.761643
  45. **Bhatia R, Kizilbash SJ, Ahrens SP, et al.** Outcomes of adolescent-onset postural orthostatic tachycardia syndrome. *J Pediatr* 2016; 173:149–153. doi:10.1016/j.jpeds.2016.02.035
  46. **George SA, Bivens TB, Howden EJ, et al.** The international POTS registry: evaluating the efficacy of an exercise training intervention in a community setting. *Heart Rhythm* 2016; 13(4):943–950. doi:10.1016/j.hrthm.2015.12.012
  47. **Fu Q, VanGundy TB, Galbreath MM, et al.** Cardiac origins of the postural orthostatic tachycardia syndrome. *J Am Coll Cardiol* 2010; 55(25):2858–2868. doi:10.1016/j.jacc.2010.02.043
  48. **Raj SR.** Row, row, row your way to treating postural tachycardia syndrome. *Heart Rhythm* 2016; 13(4):951–952. doi:10.1016/j.hrthm.2015.12.039
  49. **Celedonio JE, Garland EM, Nwazue VC, et al.** Effects of high sodium intake on blood volume and catecholamines in patients with postural tachycardia syndrome and healthy females [abstract]. *Clin Auton Res* 2014; 24:211.
  50. **Garland EM, Celedonio JE, Raj SR.** Postural tachycardia syndrome: beyond orthostatic intolerance. *Curr Neurol Neurosci Rep* 2015; 15(9):60. doi:10.1007/s11910-015-0583-8
  51. **Gordon VM, Opfer-Gehrking TL, Novak V, Low PA.** Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome. *Clin Auton Res* 2000; 10:29–33. PMID:10750641
  52. **Jacob G, Shannon JR, Black B, et al.** Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. *Circulation* 1997; 96(2):575–580. PMID:9244228
  53. **Moak JP, Leong D, Fabian R, et al.** Intravenous hydration for management of medication-resistant orthostatic intolerance in the adolescent and young adult. *Pediatr Cardiol* 2016; 37(2):278–282. doi:10.1007/s00246-015-1274-6
  54. **Ruzieh M, Baugh A, Dasa O, et al.** Effects of intermittent intravenous saline infusions in patients with medication-refractory postural tachycardia syndrome. *J Interv Card Electrophysiol* 2017; 48(3):255–260. doi:10.1007/s10840-017-0225-y
  55. **Freitas J, Santos R, Azevedo E, Costa O, Carvalho M, de Freitas AF.** Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. *Clin Auton Res* 2000; 10(5):293–299. PMID:11198485
  56. **Lee AK, Krahn AD.** Evaluation of syncope: focus on diagnosis and treatment of neurally mediated syncope. *Expert Rev Cardiovasc Ther* 2016; 14(6):725–736. doi:10.1586/14779072.2016.1164034
  57. **Coffin ST, Black BK, Biaggioni I, et al.** Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. *Heart Rhythm* 2012; 9(9):1484–1490. doi:10.1016/j.hrthm.2012.05.002
  58. **Kanjwal K, Saeed B, Karabin B, Kanjwal Y, Sheikh M, Grubb BP.** Erythropoietin in the treatment of postural orthostatic tachycardia syndrome. *Am J Ther* 2012; 19(2):92–95. doi:10.1097/MJT.0b013e3181ef621a

## POSTURAL TACHYCARDIA

59. **Hoeldtke RD, Horvath GG, Bryner KD.** Treatment of orthostatic tachycardia with erythropoietin. *Am J Med* 1995; 99(5):525–529. pmid:7485211
60. **Raj SR, Black BK, Biaggioni I, et al.** Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. *Circulation* 2009; 120(9):725–734. doi:10.1161/CIRCULATIONAHA.108.846501
61. **McDonald C, Frith J, Newton JL.** Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. *Europace* 2011; 13(3):427–430. doi:10.1093/europace/euq390
62. **Gaffney FA, Lane LB, Pettinger W, Blomqvist G.** Effects of long-term clonidine administration on the hemodynamic and neuroendocrine postural responses of patients with dysautonomia. *Chest* 1983; 83(suppl 2):436–438. pmid:6295714
63. **Jacob G, Biaggioni I.** Idiopathic orthostatic intolerance and postural tachycardia syndromes. *Am J Med Sci* 1999; 317(2):88–101. pmid:10037112
64. **Ross AJ, Ocon AJ, Medow MS, Stewart JM.** A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome. *Clin Sci (Lond)* 2014; 126(4):289–296. doi:10.1042/CS20130222
65. **Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D.** Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. *Circulation* 2005; 111(21):2734–2340. doi:10.1161/CIRCULATIONAHA.104.497594
66. **Kanjwal K, Karabin B, Sheikh M, et al.** Pyridostigmine in the treatment of postural orthostatic tachycardia: A single-center experience. *Pacing Clin Electrophysiol* 2011; 34(6):750–755. doi:10.1111/j.1540-8159.2011.03047.x
67. **Ruzieh M, Dasa O, Pacenta A, Karabin B, Grubb B.** Droxidopa in the treatment of postural orthostatic tachycardia syndrome. *Am J Ther* 2017; 24(2):e157–e161. doi:10.1097/MJT.0000000000000468
68. **Kpaeyeh AG Jr, Mar PL, Raj V, et al.** Hemodynamic profiles and tolerability of modafinil in the treatment of POTS: a randomized placebo-controlled trial. *J Clin Psychopharmacol* 2014; 34(6):738–741. doi:10.1097/JCP.0000000000000221
69. **Lai CC, Fischer PR, Brands CK, et al.** Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and beta-blockers. *Pacing Clin Electrophysiol* 2009; 32(2):234–238. doi:10.1111/j.1540-8159.2008.02207.x

ADDRESS: Satish R. Raj, MD, MSCI, FRCPC, Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, GAC70 HRIC Building, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada; satish.raj@ucalgary.ca



31st Annual

# Intensive Review of Internal Medicine

June 10 – 14, 2019

InterContinental Hotel and Bank of America Conference Center | Cleveland, OH

Session on  
test taking strategies  
Access to 100 board  
style questions  
& answers



## HIGHLIGHTS

**Earn ABIM MOC Points**

**Free App for all Attendees!**

Access presentations anytime, anywhere. Take notes, draw, or highlight

**Audience Response System**

Interactive case & MCQ based talks with audience response system

**Meet the Professor Lunches**

Meet subspecialty speakers for one-on-one discussions

**WiFi in Meeting Room**

**Cases from *Cleveland Clinic Journal of Medicine***

Access to useful clinical cases for boards & practice from *Cleveland Clinic Journal of Medicine*



Register Today! [ccfcme.org/GoIRIM](http://ccfcme.org/GoIRIM)

This activity has been approved for AMA PRA Category 1 Credit™.